UNSPSC 51371909: Dipipanone hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C24H31NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8VY00AJ0RL, chemically known as 4,4-diphenyl-6-piperidino-3-heptanone hydrochloride but more generally known as dipipanone hydrochloride, which bears US NIH Compound Identifier 13330. European Medicines Agency schedules Dipipanone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01788MIG.

Most nations, for tariff and trade purposes, schedule dipipanone hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, DIPIPANONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dipipanone hydrochloride bears US NLM identifiers UMLS ID C0770934 and NCI Concept Code C76839. SMILES: CCC(=O)C(CC(C)N1CCCCC1)(C2CCCCC2)C3CCCCC3.CL.

UNSPSC 51371909 Dipipanone hydrochloride is a Commodity code that in recent state and local procurement activity does not appear to align with the actual goods and services being solicited. The recent opportunities tagged to this code involve naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs—none of which are dipipanone hydrochloride, a synthetic opioid analgesic with controlled-substance status that does not appear in any of the posted solicitations. State and local governments do solicit pharmaceuticals, including controlled substances, through health departments, county health systems, and cooperative purchasing alliances, but the current activity under this code does not support dipipanone hydrochloride procurement.

The three most recent opportunities posted under this code between January and July 2026 span different jurisdictional buyers and procurement mechanisms. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems for community health initiatives. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The geographic spread reflects Florida, Texas, and the Upper Midwest, but the mismatch between the code name and the actual procurement scope suggests this code may be incorrectly applied to these opportunities or carries outdated classification metadata.